دورية أكاديمية
Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience
| العنوان: | Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience |
|---|---|
| المؤلفون: | Sakamoto, Yuichi, Mariya, Yasushi, Oshikiri, Toshiyuki, Sasaki, Sumiko, Segawa, Megumi, Teshiromori, Ryuichi, Ogura, Kazuto, Akagi, Tomoaki, Kaimori, Mitsuomi, Kubo, Kohmei |
| المصدر: | Acta Medica Okayama |
| بيانات النشر: | Okayama University Medical School |
| سنة النشر: | 2016 |
| المجموعة: | Okayama University Scientific Achievement Repository / 岡山大学学術成果リポジトリ |
| مصطلحات موضوعية: | chronic myeloid leukemia (CML), BCR-ABL, minimal residual disease (MRD), imatinib mesylate, real-time quantitative PCR (RQ-PCR) |
| الوصف: | Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0386-300X |
| العلاقة: | info:pmid/22037271; https://ousar.lib.okayama-u.ac.jp/files/public/4/47016/20160528085747907652/65_5_335.pdfTest; AA00508441; https://ousar.lib.okayama-u.ac.jp/47016Test |
| DOI: | 10.18926/AMO/47016 |
| الإتاحة: | https://doi.org/10.18926/AMO/47016Test https://ousar.lib.okayama-u.ac.jp/files/public/4/47016/20160528085747907652/65_5_335.pdfTest https://ousar.lib.okayama-u.ac.jp/47016Test |
| حقوق: | CopyrightⒸ 2011 by Okayama University Medical School |
| رقم الانضمام: | edsbas.819304F7 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 0386300X |
|---|---|
| DOI: | 10.18926/AMO/47016 |